DiaMedica Doses First Patients in Phase 2 Trial for Fetal Growth Restriction Treatment
Event summary
- DiaMedica dosed the first two patients in a Phase 2 trial of DM199 for fetal growth restriction (FGR) on June 23, 2026.
- The open-label, single-arm study will evaluate three dose levels of DM199 in up to 30 patients with early-onset FGR.
- DM199 aims to improve placental perfusion by dilating maternal vessels, addressing a condition with no approved pharmacologic therapies.
- The trial is investigator-sponsored and led by Catherine Cluver, MD, PhD, at Stellenbosch University.
The big picture
DiaMedica’s Phase 2 trial marks the first clinical evaluation of DM199 for fetal growth restriction, a condition with significant unmet medical needs. The study targets a critical gap in maternal-fetal medicine, where current management is limited to monitoring and timing delivery. Success could expand DiaMedica’s pipeline beyond preeclampsia and acute ischemic stroke into another high-impact therapeutic area.
What we're watching
- Clinical Efficacy
- Whether DM199 can demonstrate safety and preliminary efficacy in improving fetal growth trajectories.
- Regulatory Pathway
- The pace at which DiaMedica advances DM199 through subsequent clinical stages given the lack of prior treatments for FGR.
- Market Opportunity
- How successful outcomes in this trial could position DM199 as a first-in-class therapy for a condition affecting 10% of pregnancies globally.